Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: In vitro plasma inactivation and pharmacological activity of its main metabolites
- 18 March 2010
- journal article
- review article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 39 (5) , 283-290
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological ProfileThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2009
- Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary DiseaseAnnals of Internal Medicine, 2008
- Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: BronchodilatorsProceedings of the American Thoracic Society, 2007
- Pooled Clinical Trial Analysis of Tiotropium SafetyChest, 2006
- Anticholinergic agents in asthma and COPDEuropean Journal of Pharmacology, 2006
- Chronic obstructive pulmonary disease: current burden and future projectionsEuropean Respiratory Journal, 2006
- Ipratropium BromideNew England Journal of Medicine, 1988
- Role of the Parasympathetic System in Airway Obstruction Due to EmphysemaNew England Journal of Medicine, 1984
- Anticholinergic, Antimuscarinic BronchodilatorsAmerican Review of Respiratory Disease, 1984